The findings of this study provide a proof of concept that pharmacological inhibition of ATM can enhance the cytotoxicity of Topo-II poisons such as Etoposide in breast cancer cells, supporting the rationale for targeting the DNA damage response as a therapeutic strategy. The gene discussed is ATM; the disease is breast carcinoma.